Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
| ▸ | CASP1 | P29466 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | CASP7 | P55210 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454524 | 1.00 | ADK (1.00) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL31433473 | 1.00 | ADK (1.00) | ADKKDM4EMEN1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL29941043 | 0.99 | ADK (1.00) | ADKKDM4EMEN1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL29940884 | 0.99 | ADK (1.00) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL2036328 | 0.91 | ADK (1.00) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL2035229 | 0.91 | ADK (0.84) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL8267958 | 0.91 | ADK (0.83) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL8193961 | 0.90 | ADK (0.98) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL2037666 | 0.90 | ADK (0.82) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL8258006 | 0.90 | ADK (0.81) | ADKKDM4EMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-24 | — | — | US | claimed |
| EP-2513298-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2012-10-24 | — | — | EP | claimed |
| WO-2011075665-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-23 | — | — | WO | claimed |
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-20 | — | — | US | claimed |
| WO-2004012769-A1 | THERAPEUTIC INHIBITIONOF PROTEIN KINASES IN CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | claimed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | claimed |
| WO-2024078118-A1 | CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2024-04-18 | — | — | WO | disclosed |
| US-20200384115-A1 | TARGETED DELIVERY TO BETA CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-10 | — | — | US | disclosed |
| US-20190038627-A1 | METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE | LEGACY EMANUEL HOSPITAL & HEALTH CENTER (US) | 2019-02-07 | — | — | US | disclosed |
| US-10016432-B2 | Methanocarba derivatives of pseudoribose that inhibit adenosine kinase | LEGACY EMANUEL HOSPITAL & HEALTH CENTER (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180148428-A1 | ORGANIC LIGHT EMITTING DEVICE WITH THERMALLY ACTIVATED DELAYED FLUORESCENT LIGHT EMITTING MATERIAL | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2018-05-31 | — | — | US | disclosed |
| WO-2017205848-A1 | METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE | LEGACY EMANUEL HOSPITAL & HEALTH CENTER (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170340640-A1 | METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE | LEGACY EMANUEL HOSPITAL & HEALTH CENTER (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2004012746-A2 | NEW USES FOR INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004012769-A1 | THERAPEUTIC INHIBITIONOF PROTEIN KINASES IN CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | disclosed |
| US-6489356-B2 | TREATING HYPER-EXCITED SENSORY NERVE FUNCTIONS, COMPRISING ADMINISTERING (2-AMINO-4,5,6,7-TETRAHYDROBENZO(B)THIOPHEN-3-YL)(4-CHLOROPHENYL) METHANONE OR A ACCEPTABLE SALT THEREOF | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020055535-A1 | Method for treating pain in humans | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0989986-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO 2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | Abbott Laboratories (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1998046605-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200384115-A1 | TARGETED DELIVERY TO BETA CELLS | IAPP, ZFR, ZC3H11A | ADK 2148/4885KDM4E 1462/4885MEN1 2406/4885 |
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | ADK, AHCY, IAPP | ADK 1/4885KDM4E 1516/4885MEN1 1636/4885 |
| US-10016432-B2 | Methanocarba derivatives of pseudoribose that inhibit adenosine kinase | ADK, AK2, PRKAA1 | ADK 1/4885KDM4E 803/4885MEN1 2427/4885 |
| US-20190038627-A1 | METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE | ADK, AK2, PRKAA1 | ADK 1/4885KDM4E 803/4885MEN1 2427/4885 |
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | IMPDH1, IMPDH2, DCK | ADK 8/4885KDM4E 2094/4885MEN1 2274/4885 |
| US-20180148428-A1 | ORGANIC LIGHT EMITTING DEVICE WITH THERMALLY ACTIVATED DELAYED FLUORESCENT LIGHT EMITTING MATERIAL | OCIAD1, OCIAD2, TRPA1 | ADK 2764/4885KDM4E 4198/4885MEN1 4579/4885 |
| US-20020055535-A1 | Method for treating pain in humans | ADORA2A, ADORA2B, ADORA1 | ADK 132/4885KDM4E 2348/4885MEN1 443/4885 |
| US-20170340640-A1 | METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE | ADK, AK2, PRKAA1 | ADK 1/4885KDM4E 803/4885MEN1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.